Reclassification of oligoastrocytomas by loss of heterozygosity studies

International Journal of Cancer

Volumn 119, Issue 1, 2006, Pages 84-90

  Eoli, Marica ^a   Bissola, Lorena ^a   Bruzzone, Maria Grazia ^a   Pollo, Bianca ^a   Maccagnano, Carmelo ^a   De Simone, Tiziana ^a   Valletta, Lorella ^a   Silvani, Antonio ^a   Bianchessi, D ^a   Broggi, Giovanni ^a   Boiardi, Amerigo ^a   Finocchiaro, Gaetano ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

LOH 10; LOH 17p; LOH 19q; LOH 1p; MRI; Oligoastrocytoma

Indexed keywords

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME 10Q; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; CONTRAST ENHANCEMENT; FEMALE; GENE REARRANGEMENT; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL;

ADULT; ANALYSIS OF VARIANCE; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 19; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 33646513521     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21759     Document Type: Article

References (35)

1. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215-25, discussion 26-9.
2. Engelhard HH, Stelea A, Cochran EJ. Oligodendroglioma: pathology and molecular biology. Surg Neurol 2002;58:111-17; discussion 17.
3. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, Bellotti C. Prognostic factors in oligodendroglioma. Can J Neurol Sci 1997;24:313-19.
4. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994;145:1175-90.
5. Ueki K, Nishikawa R. Nakazato Y, Hirose T. Hirato J, Funada N, Fujimaki T, Hojo S, Kubo O, Ide T, Usui M, Ochiai C, et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002;8:196-201.
6. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
7. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004;14:121-30.
8. Bissola L, Eoli M, Pollo B, Merciai BM, Silvani A, Salsano E, Maccagnano C, Bruzzone MG, Fuhrman Conti AM, Solero CL, Giombini S, Broggi G, et al. Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. Ann Neurol 2002;52:842-5.
9. Buckner JC, Gesme D, Jr, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003;21:251-5.
10. Nakamura M, Yang F, Fujisawa H, Yonekawa Y, Kleihues P, Ohgaki H. Loss of heterozygosity on chromosome 19 in secondary glioblastomas. J Neuropathol Exp Neurol 2000;59:539-43.
11. Bello MJ, Vaquero J, de Campos JM. Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A, Rey JA. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 1994;57:172-5.
12. Wooten EC, Fults D, Duggirala R, Williams K, Kyritsis AP, Bondy ML, Levin VA, O'Connell P. A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution. Neuro-oncol 1999;1:169-76.
13. Schmidt MC, Antweiler S, Urban N, Mueller W, Kuklik A, Meyer-Puttlitz B, Wiestler OD, Louis DN, Fimmers R, von Deimling A. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-8.
14. He J, Mokhtari K, Sanson M, Marie Y, Kujas M, Huguet S, Leuraud P, Capelle L, Delattre JY, Poirier J, Hoang-Xuan K. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol 2001;60:863-71.
15. Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004;63:314-22.
16. Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, Leuraud P, Capelle L, Delattre JY, Poirier J, Broet P, Sanson M. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001;57:1278-81.
17. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103:802-9.
18. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 2003;61:267-73.
19. Mollemann M, Woher M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005;113:379-85.
20. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
21. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871-4.
22. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19ql3 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005;11:1119-28.
23. Nakatani K, Nishioka J, Itakura T, Nakanishi Y, Horinouchi J, Abe Y, Wada H, Nobori T. Cell cycle-dependent transcriptional regulation of calmodulin-binding transcription activator 1 in neuroblastoma cells. Int J Oncol 2004;24:1407-12.
24. Steele-Perkins G, Fang W, Yang XH, Van Gele M, Carling T, Gu J, Buyse IM, Fletcher JA, Liu J, Bronson R, Chadwick RB, de la Chapelle A, et al. Tumor formation and inactivation of R1Z1, an Rb-binding member of a nuclear protein-methyltransferase superfamily. Genes Dev 2001;15:2250-62.
25. Alonso ME, Bello MJ, Arjona D, Gonzalez-Gomez P, Aminoso C, Lopez-Marin I, de Campos JM, Isla A, Vaquera J, Gutierrez M, Sarasa JL, Rey JA. Mutational study of the 1p located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligodendrogliomas. Oncol Rep 2005;13:539-42.
26. Geli J, Nord B, Frisk T, Edstrom Elder E, Ekstrom TJ, Carling T, Backdahl M, Larsson C. Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas. Int J Oncol 2005;26:1385-91.
27. Barker FG, II, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, Wilson CB, Prados MD. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997;80:936-41.
28. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 2002;59:947-9.
29. Mueller W, Hartmann C, Hoffmann A, Lanksch W, Kiwit J, Tonn J. Veelken J, Schramm J, Weller M, Wiestler OD, Louis DN, von Deimling A. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol 2002;161:313-9.
30. Zlatescu MC, TehraniYazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, Caimcross JG. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713-5.
31. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-30.
32. Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R, Trinkaus K, Lytle R, Perry A. Clinical utility of fluorescence in situ hybridization (FISH) in morphologically ambiguous gliomas with hybrid oligodendroglial/astrocytic features. J Neuropathol Exp Neurol 2003;62:1118-28.
33. Mokhtari K, Paris S, Aguirre-Cruz L, Privat N, Criniere E, Marie Y, Hauw JJ, Kujas M, Rowitch D, Hoang-Xuan K, Delattre JY, Sanson M. Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification. Neuropathol Appl Neurobiol 2005;31:62-9.
34. Idbaih A, Marie Y, Pierron G, Brennetot C, Hoang-Xuan K, Kujas M, Mokhtari K, Sanson M, Lejeune J, Aurias A, Delattre O, Delattre JY. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol 2005;58:483-7.
35. Iuchi T, Namba H, Iwadate Y, Shishikura T, Kageyama H, Nakamura Y, Ohira M, Yamaura A, Osato K, Sakiyama S, Nakagawara A. Identification of the small interstitial deletion at chromosome band 1p34-p35 and its association with poor outcome in oligodendroglial tumors. Genes Chromosomes Cancer 2002;35:170-5.